STAT3 and glioblastoma: Similar to patients with breast cancer and glioblastoma, a survival analysis of 70 patients with HNSCCs demonstrated that patients with high nuclear STAT3-expressing tumors by immunohistochemistry had improved progression-free survival and lower risk of death than did patients with lower STAT3-expressing tumors [64].